In a filing, BioXcel Therapeutics Inc revealed its insider O’Neill Vincent unloaded Company’s shares for reported $58.0 on Dec 16 ’24. In the deal valued at $0.35 per share,165 shares were sold. As a result of this transaction, O’Neill Vincent now holds 19,957 shares worth roughly $9379.789999999999.
Then, Mehta Vimal sold 3,117 shares, generating $1,131 in total proceeds. Upon selling the shares at $0.36, the CEO and President now owns 59,605 shares.
Before that, Steinhart Richard I sold 577 shares. BioXcel Therapeutics Inc shares valued at $207 were divested by the Chief Financial Officer at a price of $0.36 per share. As a result of the transaction, Steinhart Richard I now holds 20,932 shares, worth roughly $9838.039999999999.
UBS downgraded its BioXcel Therapeutics Inc [BTAI] rating to a Neutral from a a Buy in a research note published on February 21, 2024; the price target was decreased to $4 from $9. A number of analysts have revised their coverage, including Mizuho’s analysts, who decreased its forecast for the stock in mid August from “a Buy” to “a Neutral”. Guggenheim also remained covering BTAI and has decreased its forecast on July 17, 2023 with a “Neutral” recommendation from previously “Buy” rating. Jefferies revised its rating on March 10, 2023. It rated BTAI as “a Hold” which previously was an “a Buy”.
Price Performance Review of BTAI
On Tuesday, BioXcel Therapeutics Inc [NASDAQ:BTAI] saw its stock fall -17.78% to $0.47. Over the last five days, the stock has gained 28.45%. BioXcel Therapeutics Inc shares have risen nearly 26.05% since the year began. Nevertheless, the stocks have fallen -83.23% over the past one year. While a 52-week high of $4.17 was reached on 01/06/25, a 52-week low of $0.30 was recorded on 01/02/25. SMA at 50 days reached $0.5043, while 200 days put it at $1.1752.
Levels Of Support And Resistance For BTAI Stock
The 24-hour chart illustrates a support level at 0.4125, which if violated will result in even more drops to 0.3537. On the upside, there is a resistance level at 0.5508. A further resistance level may holdings at 0.6303. The Relative Strength Index (RSI) on the 14-day chart is 54.08, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.0964, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 38.51%. Stochastics %K at 70.46% indicates the stock is a holding.
How much short interest is there in BioXcel Therapeutics Inc?
A steep rise in short interest was recorded in BioXcel Therapeutics Inc stocks on 2024-10-31, dropping by -0.17 million shares to a total of 0.35 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-30 was 0.52 million shares. There was a decline of -48.78%, which implies that there is a negative sentiment for the stock.
